RxDoctor Payments Data

D Koehler, MD

Internal Medicine · Delaware, OHNPI 1316031594

Payments from drug & device makers

$482in general payments, 2019–2025

Across 47 payments — averaging $10.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$338
  • Bayer$58
  • AbbVie$26
  • Pfizer$24
  • AstraZeneca$13
  • Lilly USA, LLC$12
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$47198%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$482 in reported general payments places this provider in the 65th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$80,453
Medicare patients
546
Services billed
1,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide141$134,896
EliquisApixaban107$113,262
JardianceEmpagliflozin58$81,105
TrulicityDulaglutide63$61,849
FarxigaDapagliflozin Propanediol38$39,760
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$28,426
RybelsusSemaglutide11$25,413
MyrbetriqMirabegron22$19,671
JanuviaSitagliptin Phosphate15$17,232
Tresiba Flextouch U-100Insulin Degludec19$10,756
Breo ElliptaFluticasone/Vilanterol14$10,674
Rosuvastatin Calcium581$7,465
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,841
Arnuity ElliptaFluticasone Furoate16$4,988
Varenicline Tartrate16$4,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$338$160,308152 claims
PfizerEliquis$24$113,262107 claims
Lilly USA, LLCTrulicity$12$61,84963 claims
AstraZenecaFarxiga$13$39,76038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Delaware

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →